|
|
|
|
|
|
|
|
|
|
|
| Category |
Health: Public_Health
|
|
| Category 2 |
Science: Biochemistry
|
|
| Category 3 |
Science: Biotechnology
|
|
|
|
|
|
|
|
|
|
| Description |
Improving products’ effective clinical safety will increase the industry’s fundamental value proposition to patients, healthcare providers, payors and regulators. The program will focus on pharmacovigilance program implementation and specific strategies and approaches to creating true value from a peri- and post-approval drug safety program. Drug safety programs and monitoring and the approach of this conference are not to look at safety in the silos of early-phase safety or post-approval safety but to view safety holistically, across the lifecycle, especially at the transition from approval to broader use in the marketplace.
www.healthtech.com
|
|
|
|
